[Pharmacokinetic and clinical research on a new aminoglycoside antibiotic: sisomicin].
Results obtained with sisomycin in 10 cases of purulent meningitis and 4 of bronchopulmonitis showed good tissue diffusion, together with CSF concentrations sufficient to inhibit the main aetiological agents in these forms: MIC 0.02 mg/ml for both D. pneumoniae (I-ATCC 6301) and N. meningitidis (C-ATCC 13101), i.e. liquor transfer of the antibiotic more than sufficient to handle these agents.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D001996:Bronchopneumonia / Q000188:drug therapy*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008581:Meningitis / Q000188:drug therapy*; D008589:Meningococcal Infections / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000188:drug therapy*; D012853:Sisomicin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D005839:Gentamicins; D012853:Sisomicin
Ricerca farmacocinetica e clinica su un nuovo antibiotico aminoglicosidico: sisomicina.